November 30, 2006 (Chicago) -- Magnetic resonance spectroscopic imaging (MRSI) shows no advantages over magnetic resonance imaging (MRI) alone for localization of peripheral zone prostate cancer in ...
Radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC): Results from a randomized, placebo-controlled, phase II study No significant financial relationships to disclose.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback